Low High-Density Lipoprotein Cholesterol and Chronic Disease Risk. Marker or Causal?

Journal of the American College of Cardiology

Volumn 55, Issue 25, 2010, Pages 2855-2857

  Robinson, Jennifer G ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

cancer; high density lipoprotein cholesterol; lipids; randomized, controlled trials

Indexed keywords

ALPHA TOCOPHEROL; ANACETRAPIB; BETA CAROTENE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CLOFIBRATE; DALCETRAPIB; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; TORCETRAPIB; UNCLASSIFIED DRUG;

CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG RESEARCH; EDITORIAL; HUMAN; NEOPLASM; PRIORITY JOURNAL; RISK ASSESSMENT; VITAMIN SUPPLEMENTATION;

ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHRONIC DISEASE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INCIDENCE; MALE; NEOPLASMS; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 77953311824     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.01.053     Document Type: Editorial

References (28)

1. Gordon D., Probstfield J., Garrison R., et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79 (1989) 8-15
2. Jafri H., Alsheikh-Ali A.A., and Karas R.H. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 55 (2010) 2846-2854
3. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121 (2010) e46-e215
4. Ahn J., Lim U., Weinstein S.J., et al. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 18 (2009) 2814-2821
5. Sherwin R.W., Wentworth D.N., Cutler J.A., Hulley S.B., Kuller L.H., and Stamler J. Serum cholesterol levels and cancer mortality in 361662 men screened for the Multiple Risk Factor Intervention Trial. JAMA 257 (1987) 943-948
6. Alsheikh-Ali A.A., Trikalinos T., Kent D.M., and Karas R.H. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 52 (2008) 1141-1147
7. Pencina M.J., D'Agostino Sr. R.B., Larson M.G., Massaro J.M., and Vasan R.S. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 119 (2009) 3078-3084
8. Robinson J.G., and Davidson M.H. Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport. Fut Lipidol 2 (2007) 285-301
9. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., and Fogelman A.M. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes 58 (2009) 2711-2717
10. Davidson M.H., and Rosenson R.S. Novel targets that affect high-density lipoprotein metabolism: the next frontier. Am J Cardiol 104 Suppl 10 (2009) 52E-57E
11. Ettinger Jr. W.H., Harris T., Verdery R.B., Tracy R., and Kouba E. Evidence for inflammation as a cause of hypocholesterolemia in older people. J Am Geriatr Soc 43 (1995) 264-266
12. Engels E.A. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther 8 (2008) 605-615
13. Grundy S.M. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 47 (2006) 1093-1100
14. Eyre H., Kahn R., Robertson R.M., et al. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation 109 (2004) 3244-3255
15. Singh I.M., Shishehbor M.H., and Ansell B.J. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298 (2007) 786-798
16. Furberg A.S., Veierød M.B., Wilsgaard T., Bernstein L., and Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 96 (2004) 1152-1160
17. Kronmal R., Cain K., Ye Z., and Omenn G. Total serum cholesterol levels and mortality risk as a function of age. Arch Intern Med 153 (1993) 1065-1073
18. Lewington S., Whitlock G., Clarke R., et al., Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370 (2007) 1829-1839
19. Canner P., Berge K., Wenger N., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
20. Tenkanen L., Mänttäri M., Kovanen P.T., Virkkunen H., and Manninen V. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 166 (2006) 743-748
21. Rubins H., Robins S., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
22. Huttunen J.K., Heinonen O.P., Manninen V., et al. The Helsinki Heart Study: an 8.5 year safety and mortality follow-up. J Intern Med 235 (1994) 31-39
23. Keech A., Simes R.J., Barter P., et al., FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
24. Briel M., Ferreira-Gonzalez I., You J.J., et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 338 (2009) b92
25. Kastelein J.J.P., and Bots M.L. Statin therapy with ezetimibe or niacin in high-risk patients. N Engl J Med 361 (2009) 2180-2183
26. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 361 (2009) 2113-2122
27. Koropatnick T.A., Kimbell J., Chen R., et al. A prospective study of high-density lipoprotein cholesterol, cholesteryl ester transfer protein gene variants, and healthy aging in very old Japanese-American men. J Gerontol A Biol Sci Med Sci 63 (2008) 1235-1240
28. Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol 104 Suppl 1 (2009) 10E-15E